Comparison and evaluation of two different methods to establish the cigarette smoke exposure mouse model of COPD

Sci Rep. 2017 Nov 13;7(1):15454. doi: 10.1038/s41598-017-15685-y.

Abstract

Animal model of cigarette smoke (CS) -induced chronic obstructive pulmonary disease (COPD) is the primary testing methodology for drug therapies and studies on pathogenic mechanisms of disease. However, researchers have rarely run simultaneous or side-by-side tests of whole-body and nose-only CS exposure in building their mouse models of COPD. We compared and evaluated these two different methods of CS exposure, plus airway Lipopolysaccharides (LPS) inhalation, in building our COPD mouse model. Compared with the control group, CS exposed mice showed significant increased inspiratory resistance, functional residual capacity, right ventricular hypertrophy index, and total cell count in BALF. Moreover, histological staining exhibited goblet cell hyperplasia, lung inflammation, thickening of smooth muscle layer on bronchia, and lung angiogenesis in both methods of CS exposure. Our data indicated that a viable mouse model of COPD can be established by combining the results from whole-body CS exposure, nose-only CS exposure, and airway LPS inhalation testing. However, in our study, we also found that, given the same amount of particulate intake, changes in right ventricular pressure and intimal thickening of pulmonary small artery are a little more serious in nose-only CS exposure method than changes in the whole-body CS exposure method.

Publication types

  • Comparative Study
  • Evaluation Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Administration, Inhalation
  • Animals
  • Bronchoalveolar Lavage Fluid
  • Disease Models, Animal*
  • Lipopolysaccharides / administration & dosage
  • Lipopolysaccharides / toxicity
  • Lung / pathology
  • Mice
  • Mice, Inbred C57BL
  • Nicotiana / adverse effects*
  • Pulmonary Disease, Chronic Obstructive / diagnosis
  • Pulmonary Disease, Chronic Obstructive / etiology*
  • Pulmonary Disease, Chronic Obstructive / pathology
  • Respiratory Function Tests
  • Smoke / adverse effects*
  • Smoking / adverse effects

Substances

  • Lipopolysaccharides
  • Smoke